Login to Your Account



Biovail Returns 5th Program, Cortex Gets Ampakine Assets

By Tom Wall


Thursday, March 17, 2011
A year after agreeing to a $10 million up-front, $15 million milestones deal with Biovail SRL to develop Ampakine compounds for respiratory depression treatments, Cortex Pharmaceuticals Inc. is getting back all of the Ampakine assets and intellectual property it sold. (See BioWorld Today, March 29, 2010.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription